GlaxoSmithKline plc Falls On Slumping Sales

GlaxoSmithKline plc (LON: GSK) contends with a slow start to 2014 but is confident of “improving” product portfolio and remains upbeat on Novartis tie-up

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in GlaxoSmithKline (LSE: GSK) fell a little over 1% to 1,642p after the UK’s largest healthcare company posted a 10% sales decline in the first quarter. This was mainly a reflection of sterling’s strength against the US dollar and the Euro, while at constant exchange rates sales grew in all major markets barring the US. Total sales still fell 2% in constant exchange rate terms. 

GlaxoSmithKlineDespite falling sales, core earnings per share increased to 21p while the quarterly dividend rose 6% to 19p. Glaxo is targeting share buybacks of £1-2bn in 2014.

GSK noted that the deal to trade assets with Swiss company Novartis — Glaxo will sell its oncology division, while gaining Novartis’ vaccines business — should enhance the firm’s long term earnings outlook.

At constant exchange rates Glaxo expects sales to grow in 2014 — dependent on a number of factors, including the rollout of new medicines and the level of generic competition to older products.

The chief executive, Sir Andrew Witty, commented:

“We are very focused on executing the roll-out of our new products and are re-allocating investment to do so.  In an industry with 20-year product cycles, synchronisation of this new product growth with managing the impact of competition elsewhere in the portfolio is clearly challenging, particularly in the US, and especially when viewed on a quarterly basis.”

“We remain confident that GSK’s overall portfolio is fundamentally changing and improving.  The R&D innovations we are now launching are at the forefront of an extensive pipeline and discovery effort supporting our strategic approach to deliver a continued flow of multiple product launches that are competitive and will be valued by both patients and payers.”

After this morning’s price movement, GlaxoSmithKline shares offer a prospective dividend yield of 4.7%. The shares trade on a forward P/E of 15 against the FTSE 100 average of 13.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Mark does not own shares in any company mentioned. The Motley Fool recommends shares in GlaxoSmithKline.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is Avon Protection the best stock to buy in the FTSE All-Share index right now?

Here’s a stock I’m holding for recovery and growth from the FTSE All-Share index. Can it be crowned as the…

Read more »

Investing Articles

Down 8.5% this month, is the Aviva share price too attractive to ignore?

It’s time to look into Aviva and the insurance sector while the share price is pulling back from year-to-date highs.

Read more »

Investing Articles

Here’s where I see Vodafone’s share price ending 2024

Valued at just twice its earnings, is the Vodafone share price a bargain or value trap? Our writer explores where…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »

Dividend Shares

850 shares in this dividend giant could make me £1.1k in passive income

Jon Smith flags up one dividend stock for passive income that has outperformed its sector over the course of the…

Read more »

Investing Articles

Unilever shares are flying! Time to buy at a 21% ‘discount’?

Unilever shares have been racing higher this week after a one-two punch of news from the company. Here’s whether I…

Read more »

artificial intelligence investing algorithms
Market Movers

The Microsoft share price surges after results. Is this the best AI stock to buy?

Jon Smith flags up the jump in the Microsoft share price after the latest results showed strong demand for AI…

Read more »

Google office headquarters
Investing Articles

A dividend announcement sends the Alphabet share price soaring. Here’s what investors need to know

As the Alphabet share price surges on the announcement of a dividend, Stephen Wright outlines what investors should really be…

Read more »